Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.

Michelle Magid, Jason S. Reichenberg, Poppy E. Poth, Henry T. Robertson, Amanda K. LaViolette, Tillmann H C Kruger, M. Axel Wollmer

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

To determine whether a single treatment of botulinum toxin A in the forehead (glabellar) region can improve symptoms of depression in patients with major depressive disorder (MDD), as defined by DSM-IV criteria. Thirty participants were randomly assigned to receive either placebo or botulinum toxin A (BTA; onabotulinumtoxinA) injections in the forehead. Female participants received 29 units; male participants received 39 units. At week 12, the groups were crossed over. Participants were evaluated at weeks 0, 3, 6, 12, 15, 18, and 24 for improvement in MDD symptoms using the Patient Health Care Questionnaire-9, Beck Depression Inventory (BDI), and 21-Item Hamilton Depression Rating Scale (HDRS-21) objective measurement scales. The primary outcome was the rate of HDRS-21 response, defined as ≥ 50% score reduction from baseline. The study occurred from July 2011 to November 2012. Patients who received BTA at week 0 (BTA-first group) and at week 12 (BTA-second group) had a statistically significant reduction in MDD symptoms as compared to placebo. Improvement in MDD continued over 24 weeks in the group that received BTA first even though the cosmetic effects of BTA wore off at 12 to 16 weeks. HDRS-21 response rates were 55% (6/11) in the BTA-first group, 24% (4/17) in the BTA-second group, and 0% (0/19) in the placebo group (P < .0001). HDRS-21 remission rates (score ≤ 7) were 18% (2/11), 18% (3/17), and 0% (0/19), respectively (P = .057). HDRS-21 scores dropped -46% and -35% in the BTA-first and -second groups versus -2% in the placebo group (P < .0001). The BDI response rate (≥ 50% reduction from baseline) was 45% (5/11) in the BTA-first group, 33% (6/18) in the BTA-second group, and 5% (1/19) in the placebo group (P = .0067). BDI remission rates (score ≤ 9) were 27% (3/11), 33% (6/18), and 5% (1/19), respectively (P = .09). BDI scores dropped -42% and -35% in the BTA-first and -second groups versus -15% in the placebo group (P < .0001). Botulinum toxin A injection in the glabellar region was associated with significant improvement in depressive symptoms and may be a safe and sustainable intervention in the treatment of MDD. ClinicalTrials.gov identifier: NCT01392963.

Original languageEnglish (US)
Pages (from-to)837-844
Number of pages8
JournalThe Journal of clinical psychiatry
Volume75
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Type A Botulinum Toxins
Major Depressive Disorder
Placebos
Depression
Equipment and Supplies
Forehead
Therapeutics
Injections
Cosmetics
Diagnostic and Statistical Manual of Mental Disorders
Patient Care
Delivery of Health Care

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Magid, M., Reichenberg, J. S., Poth, P. E., Robertson, H. T., LaViolette, A. K., Kruger, T. H. C., & Wollmer, M. A. (2014). Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry, 75(8), 837-844. https://doi.org/10.4088/JCP.13m08845

Treatment of major depressive disorder using botulinum toxin A : a 24-week randomized, double-blind, placebo-controlled study. / Magid, Michelle; Reichenberg, Jason S.; Poth, Poppy E.; Robertson, Henry T.; LaViolette, Amanda K.; Kruger, Tillmann H C; Wollmer, M. Axel.

In: The Journal of clinical psychiatry, Vol. 75, No. 8, 2014, p. 837-844.

Research output: Contribution to journalArticle

Magid, M, Reichenberg, JS, Poth, PE, Robertson, HT, LaViolette, AK, Kruger, THC & Wollmer, MA 2014, 'Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.', The Journal of clinical psychiatry, vol. 75, no. 8, pp. 837-844. https://doi.org/10.4088/JCP.13m08845
Magid, Michelle ; Reichenberg, Jason S. ; Poth, Poppy E. ; Robertson, Henry T. ; LaViolette, Amanda K. ; Kruger, Tillmann H C ; Wollmer, M. Axel. / Treatment of major depressive disorder using botulinum toxin A : a 24-week randomized, double-blind, placebo-controlled study. In: The Journal of clinical psychiatry. 2014 ; Vol. 75, No. 8. pp. 837-844.
@article{4a110ba3808348808c85dfaa7e25debb,
title = "Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.",
abstract = "To determine whether a single treatment of botulinum toxin A in the forehead (glabellar) region can improve symptoms of depression in patients with major depressive disorder (MDD), as defined by DSM-IV criteria. Thirty participants were randomly assigned to receive either placebo or botulinum toxin A (BTA; onabotulinumtoxinA) injections in the forehead. Female participants received 29 units; male participants received 39 units. At week 12, the groups were crossed over. Participants were evaluated at weeks 0, 3, 6, 12, 15, 18, and 24 for improvement in MDD symptoms using the Patient Health Care Questionnaire-9, Beck Depression Inventory (BDI), and 21-Item Hamilton Depression Rating Scale (HDRS-21) objective measurement scales. The primary outcome was the rate of HDRS-21 response, defined as ≥ 50{\%} score reduction from baseline. The study occurred from July 2011 to November 2012. Patients who received BTA at week 0 (BTA-first group) and at week 12 (BTA-second group) had a statistically significant reduction in MDD symptoms as compared to placebo. Improvement in MDD continued over 24 weeks in the group that received BTA first even though the cosmetic effects of BTA wore off at 12 to 16 weeks. HDRS-21 response rates were 55{\%} (6/11) in the BTA-first group, 24{\%} (4/17) in the BTA-second group, and 0{\%} (0/19) in the placebo group (P < .0001). HDRS-21 remission rates (score ≤ 7) were 18{\%} (2/11), 18{\%} (3/17), and 0{\%} (0/19), respectively (P = .057). HDRS-21 scores dropped -46{\%} and -35{\%} in the BTA-first and -second groups versus -2{\%} in the placebo group (P < .0001). The BDI response rate (≥ 50{\%} reduction from baseline) was 45{\%} (5/11) in the BTA-first group, 33{\%} (6/18) in the BTA-second group, and 5{\%} (1/19) in the placebo group (P = .0067). BDI remission rates (score ≤ 9) were 27{\%} (3/11), 33{\%} (6/18), and 5{\%} (1/19), respectively (P = .09). BDI scores dropped -42{\%} and -35{\%} in the BTA-first and -second groups versus -15{\%} in the placebo group (P < .0001). Botulinum toxin A injection in the glabellar region was associated with significant improvement in depressive symptoms and may be a safe and sustainable intervention in the treatment of MDD. ClinicalTrials.gov identifier: NCT01392963.",
author = "Michelle Magid and Reichenberg, {Jason S.} and Poth, {Poppy E.} and Robertson, {Henry T.} and LaViolette, {Amanda K.} and Kruger, {Tillmann H C} and Wollmer, {M. Axel}",
year = "2014",
doi = "10.4088/JCP.13m08845",
language = "English (US)",
volume = "75",
pages = "837--844",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Treatment of major depressive disorder using botulinum toxin A

T2 - a 24-week randomized, double-blind, placebo-controlled study.

AU - Magid, Michelle

AU - Reichenberg, Jason S.

AU - Poth, Poppy E.

AU - Robertson, Henry T.

AU - LaViolette, Amanda K.

AU - Kruger, Tillmann H C

AU - Wollmer, M. Axel

PY - 2014

Y1 - 2014

N2 - To determine whether a single treatment of botulinum toxin A in the forehead (glabellar) region can improve symptoms of depression in patients with major depressive disorder (MDD), as defined by DSM-IV criteria. Thirty participants were randomly assigned to receive either placebo or botulinum toxin A (BTA; onabotulinumtoxinA) injections in the forehead. Female participants received 29 units; male participants received 39 units. At week 12, the groups were crossed over. Participants were evaluated at weeks 0, 3, 6, 12, 15, 18, and 24 for improvement in MDD symptoms using the Patient Health Care Questionnaire-9, Beck Depression Inventory (BDI), and 21-Item Hamilton Depression Rating Scale (HDRS-21) objective measurement scales. The primary outcome was the rate of HDRS-21 response, defined as ≥ 50% score reduction from baseline. The study occurred from July 2011 to November 2012. Patients who received BTA at week 0 (BTA-first group) and at week 12 (BTA-second group) had a statistically significant reduction in MDD symptoms as compared to placebo. Improvement in MDD continued over 24 weeks in the group that received BTA first even though the cosmetic effects of BTA wore off at 12 to 16 weeks. HDRS-21 response rates were 55% (6/11) in the BTA-first group, 24% (4/17) in the BTA-second group, and 0% (0/19) in the placebo group (P < .0001). HDRS-21 remission rates (score ≤ 7) were 18% (2/11), 18% (3/17), and 0% (0/19), respectively (P = .057). HDRS-21 scores dropped -46% and -35% in the BTA-first and -second groups versus -2% in the placebo group (P < .0001). The BDI response rate (≥ 50% reduction from baseline) was 45% (5/11) in the BTA-first group, 33% (6/18) in the BTA-second group, and 5% (1/19) in the placebo group (P = .0067). BDI remission rates (score ≤ 9) were 27% (3/11), 33% (6/18), and 5% (1/19), respectively (P = .09). BDI scores dropped -42% and -35% in the BTA-first and -second groups versus -15% in the placebo group (P < .0001). Botulinum toxin A injection in the glabellar region was associated with significant improvement in depressive symptoms and may be a safe and sustainable intervention in the treatment of MDD. ClinicalTrials.gov identifier: NCT01392963.

AB - To determine whether a single treatment of botulinum toxin A in the forehead (glabellar) region can improve symptoms of depression in patients with major depressive disorder (MDD), as defined by DSM-IV criteria. Thirty participants were randomly assigned to receive either placebo or botulinum toxin A (BTA; onabotulinumtoxinA) injections in the forehead. Female participants received 29 units; male participants received 39 units. At week 12, the groups were crossed over. Participants were evaluated at weeks 0, 3, 6, 12, 15, 18, and 24 for improvement in MDD symptoms using the Patient Health Care Questionnaire-9, Beck Depression Inventory (BDI), and 21-Item Hamilton Depression Rating Scale (HDRS-21) objective measurement scales. The primary outcome was the rate of HDRS-21 response, defined as ≥ 50% score reduction from baseline. The study occurred from July 2011 to November 2012. Patients who received BTA at week 0 (BTA-first group) and at week 12 (BTA-second group) had a statistically significant reduction in MDD symptoms as compared to placebo. Improvement in MDD continued over 24 weeks in the group that received BTA first even though the cosmetic effects of BTA wore off at 12 to 16 weeks. HDRS-21 response rates were 55% (6/11) in the BTA-first group, 24% (4/17) in the BTA-second group, and 0% (0/19) in the placebo group (P < .0001). HDRS-21 remission rates (score ≤ 7) were 18% (2/11), 18% (3/17), and 0% (0/19), respectively (P = .057). HDRS-21 scores dropped -46% and -35% in the BTA-first and -second groups versus -2% in the placebo group (P < .0001). The BDI response rate (≥ 50% reduction from baseline) was 45% (5/11) in the BTA-first group, 33% (6/18) in the BTA-second group, and 5% (1/19) in the placebo group (P = .0067). BDI remission rates (score ≤ 9) were 27% (3/11), 33% (6/18), and 5% (1/19), respectively (P = .09). BDI scores dropped -42% and -35% in the BTA-first and -second groups versus -15% in the placebo group (P < .0001). Botulinum toxin A injection in the glabellar region was associated with significant improvement in depressive symptoms and may be a safe and sustainable intervention in the treatment of MDD. ClinicalTrials.gov identifier: NCT01392963.

UR - http://www.scopus.com/inward/record.url?scp=84908332158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908332158&partnerID=8YFLogxK

U2 - 10.4088/JCP.13m08845

DO - 10.4088/JCP.13m08845

M3 - Article

C2 - 24910934

AN - SCOPUS:84908332158

VL - 75

SP - 837

EP - 844

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -